A review of the treatment of psoriasis with infliximab.
Patients afflicted with moderate to severe psoriasis experience a reduction in the quality of life. They not only suffer the aggravation associated with the pain, itchiness, and bleeding of the psoriatic lesions, but also experience a negative impact on their daily functions and social well-being. Unfortunately, traditional therapeutic measures have not been effective enough in treating individuals suffering from moderate to severe forms of psoriasis. Most of the conventional medications have produced at best only partial responses. However, the recent chimeric monoclonal TNF-alpha inhibiting antibody, infliximab, has been proven effective for the treatment of patients with moderate to severe psoriasis. Most patients treated with infliximab have shown rapid and remarkable improvement in the clinical manifestations of the disease. This article will closely examine the efficacy and safety of infliximab through the analysis of past case reports and clinical trials.
Vamvouris
Theodora
T
Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029-6574, USA. tvamvouris@aol.com
Hadi
Suhail
S
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab